Vericel Corporation VCEL 深 滬
已收盤 02-06 16:00:00 美东时间
36.19
+0.810
+2.29%
華盛通- 最 高36.54
- 今 開35.69
- 成交量 49.90万股
- 最 低 34.825
- 昨 收 35.38
- 總市值 18.30亿
- 52周最高 58.77
- 市盈率 靜 180.50
- 換手率 0.99%
- 52周最低 29.24
- 委 比 -34.21%
- 總股本 5057.40万
- 歷史最高 68.94
- 量 比 1.13
- 振 幅 4.85%
- 歷史最低 1.11
- 每 手 1
- 風險率 5.95%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why Is Vericel Stock Gaining Tuesday?
Vericel Corporation (NASDAQ: VCEL) stock rose on Tuesday after announcing preliminary financial results for 2025.
01-14 01:57
Vericel expects $276 mln revenue in 2025
Vericel Corporation (VCEL) on Tuesday said that it expects preliminary full-year 2025 revenue of about $276 million, with MACI sales accounting for $239.5 million and Burn Care revenue of $36.5 millio...
01-13 22:10
Vericel Announces Preliminary 2025 Financial Results and Business Updates
Vericel Corporation reported preliminary 2025 financial results, including total revenue of $276 million, with MACI revenue at $239.5 million and Burn Care at $36.5 million. Gross margin is expected to be 74%, and adjusted EBITDA margin 26%, with GAAP Net Income profitable for the second year. The company ended 2025 with $200 million in cash and no debt. Business highlights include record MACI implants, 20% MACI revenue growth for the third conse...
01-13 14:00
Vericel to Present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026
Vericel Corporation will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 2:15 p.m. ET. A webcast of the presentation will be available on the company's Investor Relations website. Vericel, a leader in advanced therapies for sports medicine and severe burn care, markets three products in the U.S., including MACI® and Epicel®, and holds rights to NexoBrid®.
01-06 13:30
美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
2025-12-19 10:15
Truist Securities Maintains Buy on Vericel, Lowers Price Target to $45
Truist Securities analyst Richard Newitter maintains Vericel (NASDAQ:VCEL) with a Buy and lowers the price target from $50 to $45.
2025-12-19 00:10
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
2025-11-11 10:49
Truist Securities Reiterates Buy on Vericel, Raises Price Target to $50
Truist Securities analyst Richard Newitter reiterates Vericel (NASDAQ:VCEL) with a Buy and raises the price target from $41 to $50.
2025-11-11 01:17
Vericel shares are trading higher after the company reported better-than-expected Q3 financial results.
Vericel shares are trading higher after the company reported better-than-expect...
2025-11-07 01:20
Vericel to Report Third-Quarter 2025 Financial Results on November 6, 2025
Vericel Corporation announced it will release its Q3 2025 financial results on November 6, 2025, and host a conference call and webcast at 8:30 a.m. ET to discuss the results and business highlights. The live webcast will be available on the Investor Relations section of Vericel's website, with a replay until November 6, 2026. Vericel focuses on advanced therapies for sports medicine and severe burn care, offering products like MACI and Epicel, a...
2025-10-23 12:30
